Takeda Pharmaceutical Company Limited  announced this week that it has completed enrollment of 20,100 children and adolescents ages 4 through 16 in its global, pivotal Phase 3 Tetravalent Immunization...

Takeda Pharmaceutical Company Limited today announced that it has dosed the first subject in a Phase 2b field efficacy trial of Takeda’s norovirus vaccine candidate (TAK-214), the only norovirus vaccine...

Worldwide, noroviruses cause one in five cases of viral gastroenteritis and an estimated annual 300 million cases of norovirus infection contribute to roughly 260,000 deaths, mostly in low-income countries....